ado-TRASTuzumab-Emtansine (Kadcyla®)

مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

TDM1-00000-03-CN-BR

Ministry of Health

Name: **File #:** **Ht (cm):**
Nationality: **Civil ID:** **Wt (Kg):**
Gender/Age: **DOB:** **BSA (m²):**

Indication(s): HER2 +ve breast cancer, Palliative.
Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Parameters: Baseline ECHO and/or MUGA scan before initiation of Anti-HER2 therapy.
Then, every 3 months during and upon completion of Anti-HER2 therapy.
Then, every 6 months for at least 2 years following completion of Anti-HER2 therapy.

Pre-treatment Medications: (30-60 min before starting treatment)
Dexamethasone 12 mg PO/IV

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
TDM-1 (Kadcyla®)	3.6 mg/kg	IV in 250 mL NS. Initial dose over 90 min and subsequent doses over 60 min.	D1
To be repeated every 3 weeks until disease progression or intolerable toxicity.			

Treatment Description:

Cycle	Date	TDM-1	LVEF	Physician	Consultant
C# __					
C# __					
C# __					
C# __					
C# __					
C# __					

Important Notes:
Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological
If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No